GH Research PLC (NASDAQ:GHRS) Receives $30.67 Consensus PT from Brokerages

GH Research PLC (NASDAQ:GHRS) has been assigned an average recommendation of “Buy” from the six brokerages that are covering the stock, Marketbeat.com reports. Six analysts have rated the stock with a buy rating. The average 1 year target price among analysts that have covered the stock in the last year is $30.67.

A number of brokerages have recently weighed in on GHRS. Canaccord Genuity Group dropped their price objective on shares of GH Research from $31.00 to $28.00 and set a “buy” rating for the company in a research note on Monday, November 18th. HC Wainwright restated a “buy” rating and set a $40.00 target price on shares of GH Research in a report on Monday, January 27th. Cantor Fitzgerald began coverage on shares of GH Research in a report on Thursday, February 13th. They issued an “overweight” rating and a $14.00 price objective on the stock. Royal Bank of Canada began coverage on shares of GH Research in a research report on Friday. They issued an “outperform” rating and a $31.00 target price for the company. Finally, Stifel Nicolaus boosted their target price on shares of GH Research from $18.00 to $32.00 and gave the stock a “buy” rating in a research report on Thursday, February 27th.

Institutional Trading of GH Research

A number of institutional investors have recently made changes to their positions in GHRS. RA Capital Management L.P. raised its position in shares of GH Research by 1.3% in the third quarter. RA Capital Management L.P. now owns 6,686,689 shares of the company’s stock valued at $44,734,000 after purchasing an additional 85,000 shares during the period. Geode Capital Management LLC increased its position in GH Research by 4.5% in the 4th quarter. Geode Capital Management LLC now owns 72,513 shares of the company’s stock valued at $508,000 after acquiring an additional 3,092 shares during the period. Diadema Partners LP bought a new position in shares of GH Research during the fourth quarter valued at $711,000. Lynx1 Capital Management LP raised its stake in shares of GH Research by 15.8% during the fourth quarter. Lynx1 Capital Management LP now owns 4,858,994 shares of the company’s stock valued at $34,013,000 after acquiring an additional 663,100 shares during the last quarter. Finally, Northern Trust Corp raised its stake in shares of GH Research by 26.8% during the fourth quarter. Northern Trust Corp now owns 40,834 shares of the company’s stock valued at $286,000 after acquiring an additional 8,641 shares during the last quarter. Institutional investors own 56.90% of the company’s stock.

GH Research Trading Down 0.5 %

GHRS opened at $10.50 on Friday. The firm has a market capitalization of $546.29 million, a PE ratio of -13.29 and a beta of 0.94. The firm’s 50-day moving average price is $10.80 and its 200 day moving average price is $9.17. GH Research has a twelve month low of $6.00 and a twelve month high of $20.50.

GH Research (NASDAQ:GHRS) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.06. As a group, analysts predict that GH Research will post -0.8 earnings per share for the current fiscal year.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).